Aeluma, Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Aeluma, Inc. on February 24, 2025. The filing reports a corporate governance event: the election of a new independent director to the Board of Directors. The Company is an emerging growth company incorporated in Delaware.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on board composition and director compensation arrangements rather than financial performance.
Material Changes
- Board Expansion: The Board of Directors increased its size from four (4) to five (5) members.
- Class II Adjustment: Class II of the Board was increased from one (1) to two (2) members.
- New Director Election: Michael Byron was elected to fill the vacancy as a Class II Director, with a term expiring at the 2026 annual meeting.
Guidance, Outlook, and Management Commentary
There is no financial guidance or outlook provided in this filing. Management commentary focuses on the qualifications of the new director:
- Michael Byron's Background: Retired as Vice President of Finance Operations & Systems at NVIDIA in December 2024 after 22 years of service, including roles as Vice President & Chief Accounting Officer. He holds a CPA and a Bachelor's degree in Business Economics from UC Santa Barbara.
- Independence: The Board determined Mr. Byron is "independent" under Nasdaq and SEC rules.
- Compensation: Mr. Byron was granted a stock option to purchase 45,833 shares of common stock. The exercise price equals the fair market value at the time of grant. Vesting occurs in tranches: 833 shares on February 28, 2025, and 15,000 shares each on May 31, August 31, and November 30, 2025, contingent on continued service. The option includes a change-in-control acceleration provision.
Investor Verification Checklist
- Verify the total number of outstanding shares and the dilution impact of the 45,833 new options granted to Mr. Byron.
- Review the attached Director's Agreement (Exhibit 10.1) and Indemnification Agreement (Exhibit 10.2) for specific liability terms.
- Confirm the fair market value of the stock on February 24, 2025, to determine the exercise price of the granted options.
- Check subsequent filings for any changes to the Board composition or additional director appointments.